---
title: "Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286818220.md"
description: "Wave Life Sciences announced positive results from the RestorAATion-2 trial, showing that WVE-006 effectively restores M-AAT levels and reduces Z-AAT levels. In the 200 mg biweekly cohort, M-AAT reached 64% of total, while Z-AAT decreased by 71%. The 400 mg monthly dosing also showed significant results. The treatment was well tolerated with no liver toxicities. The company anticipates FDA feedback on accelerated approval by mid-2026 and plans to present further data in H2 2026."
datetime: "2026-05-18T20:53:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286818220.md)
  - [en](https://longbridge.com/en/news/286818220.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286818220.md)
---

# Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing

**Wave Life Sciences reported positive RestorAATion-2 results showing WVE-006 restores protective M-AAT and markedly reduces harmful Z-AAT.**

**Key Highlights:**

-   WVE-006 generated wild-type M-AAT at 64% of total and reduced Z-AAT by 71% in the 200 mg biweekly multidose cohort.
-   400 mg monthly multidose produced similar effects: 58.7% M-AAT and 13.6 µM total AAT, supporting monthly dosing.
-   Single-dose reductions in Z-AAT were dose-dependent: 47.3% (200 mg), 49.7% (400 mg), 59.1% (600 mg).
-   RNA editing effects were durable (sustained ≥3 months post-dose) and WVE-006 was generally well tolerated with no liver toxicities.
-   Wave expects FDA feedback on a potential accelerated approval pathway mid-2026 and will share 600 mg multidose data in H2 2026.

Original SEC Filing: Wave Life Sciences Ltd. \[ WVE \] - 8-K - May. 18, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [WVE.US](https://longbridge.com/en/quote/WVE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBC.US](https://longbridge.com/en/quote/BBC.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)